Comprehensive stability-indicating method development of Avanafil Phosphodiesterase type 5 inhibitor using advanced Quality-by-Design approach

Journal of Analytical Science and Technology

Table 1 Plackett–Burman design for screening of Primary parameters

Sr no.	A	B	C	D	E	F	G	H	I	J	K
1	70	MeOH	10	25	5	1.2	5	c18	AF	10	230
2	50	MeOH	30	10	5	1.2	20	c18	AF	5	250
3	70	ACN	30	25	3	1.2	20	c8	AF	5	230
4	50	MeOH	10	25	5	0.5	20	c8	AA	5	230
5	50	ACN	30	10	5	1.2	5	c8	AA	10	230
6	50	ACN	10	25	3	1.2	20	c18	AA	10	250
7	70	ACN	10	10	5	0.5	20	c8	AF	10	250
8	70	MeOH	10	10	3	1.2	5	c8	AA	5	250
9	70	MeOH	30	10	3	0.5	20	c18	AA	10	230
10	50	MeOH	30	25	3	0.5	5	c8	AF	10	250
11	70	ACN	30	25	5	0.5	5	c18	AA	5	250
12	50	ACN	10	10	3	0.5	5	c18	AF	5	230

A = Mobile phase ratio (Organic phase:Aqueous phase, v/v); B = Organic phase type, C = Temperature of column oven, °C; D = Degase time, min; E = pH of buffer; F = Flow rate, mL/min; G = Sample volume, μL; H = Column type; I = Buffer (AA ammonium acetate, AF ammonium formate); J = Buffer strength, mM; K = Detection wavelength, nm